Merck (NYSE: [[ticker:MRK]]) announced plans to shutter its research site in Cambridge, MA’s Kendall Square neighborhood alongside seven other research facilities worldwide over the next two years. It will also phase out another eight manufacturing sites, as part a restructuring plan that follows its November 2009 merger with Schering-Plough. Some of the Kendall Square research operations will shift across the river to Merck’s facility in Boston’s Longwood Medical Area, a company spokesman told me. New Jersey-based Merck previously announced plans to cut 15 percent of its combined 100,000-person workforce, and the moves announced today will fall under that umbrella.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
